genetically modified Shiga-toxin-2e antigen - search results

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaccines - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).the use of dengvaxia should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

tegretol cr 200 carbamazepine 200 mg tablet blister pack

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 200 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; purified talc; titanium dioxide; magnesium stearate; acrylates copolymer; peg-40 hydrogenated castor oil; hypromellose; colloidal anhydrous silica; carmellose sodium; iron oxide yellow; iron oxide red; purified water; ethylcellulose; sodium lauryl sulfate; cetyl alcohol; hydrogen peroxide; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

tegretol cr 400 carbamazepine 400 mg tablet blister pack

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 400 mg - tablet, modified release - excipient ingredients: purified talc; microcrystalline cellulose; titanium dioxide; hypromellose; acrylates copolymer; peg-40 hydrogenated castor oil; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; carmellose sodium; iron oxide red; purified water; ethylcellulose; sodium lauryl sulfate; cetyl alcohol; hydrogen peroxide; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

paracetamol 500mg effervescent tablets

cipla eu ltd - paracetamol - effervescent tablet - 500mg